A5091747797- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Immunodeficiency and Autoimmune Disorders
- Biosimilars and Bioanalytical Methods
- Immunotherapy and Immune Responses
- Pancreatitis Pathology and Treatment
- Amoebic Infections and Treatments
- Clostridium difficile and Clostridium perfringens research
- T-cell and B-cell Immunology
University of Washington
2024
T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) is an receptor on immune cells that outcompetes activating receptor, CD226, for shared ligands. Tumor-infiltrating lymphocytes express TIGIT CD226 regulatory T (Treg) CD8+ tumor-reactive or exhausted phenotypes, supporting the potential of therapeutically targeting to enhance antitumor immunity. To optimize efficacy therapeutic antibodies against TIGIT, it necessary understand IgG Fc (Fcγ) binding...
<p>Supplemental Tables 1–3</p>
<p>Figure S1</p>
<div>Abstract<p>T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) is an receptor on immune cells that outcompetes activating receptor, CD226, for shared ligands. Tumor-infiltrating lymphocytes express TIGIT CD226 regulatory T (Treg) CD8<sup>+</sup> tumor-reactive or exhausted phenotypes, supporting the potential of therapeutically targeting to enhance antitumor immunity. To optimize efficacy therapeutic antibodies against...
<p>Figure S9</p>
<p>Figure S10</p>
<p>Figure S9</p>
<p>Figure S8</p>
<p>Figure S10</p>
<p>Figure S1</p>
<p>Supplemental Tables 1–3</p>
<div>Abstract<p>T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) is an receptor on immune cells that outcompetes activating receptor, CD226, for shared ligands. Tumor-infiltrating lymphocytes express TIGIT CD226 regulatory T (Treg) CD8<sup>+</sup> tumor-reactive or exhausted phenotypes, supporting the potential of therapeutically targeting to enhance antitumor immunity. To optimize efficacy therapeutic antibodies against...
<p>Figure S8</p>
<p>Figure S5</p>
<p>Figure S7</p>
<p>Figure S4</p>
<p>Figure S5</p>
<p>Figure S6</p>
<p>Figure S2</p>
<p>Figure S3</p>
<p>Figure S7</p>
<p>Figure S4</p>
<p>Figure S6</p>
<p>Figure S2</p>
<p>Figure S3</p>